ImmunityBio’s IBRX Plummets 10% as $300M Volume Ranks 424th in U.S. Markets Amid High-Stakes BLA Submission and Competitive Pressures

Market Snapshot

On March 4, 2026, ImmunityBio (IBRX) closed with a 10.00% decline, marking a sharp reversal in a stock that had surged 386.6% year-to-date. Trading volume reached $0.30 billion, ranking 424th among all stocks on the day. Despite the recent volatility, the company’s ANKTIVA drug drove $113 million in net product revenue for 2025—a 700% year-over-year increase—and unit sales grew 750% in 2025 compared to 2024. Regulatory approvals now span 33 countries for bladder cancer and include a new lung cancer authorization in Saudi Arabia.

Key Drivers Behind the Decline

The 10% drop in IBRX’s share price reflects mounting concerns over valuation sustainability and near-term execution risks. While ANKTIVA’s commercial performance has exceeded initial expectations—$38.3 million in Q4 2025 revenue and 33-country approvals—the stock’s 386.6% YTD gain has priced in a “buy the rumor” narrative that now faces a critical test. Analysts highlight a widening expectation gap: the market has already factored in explosive growth, but the next phase—converting regulatory wins into broader commercial adoption—remains unproven.

A pivotal catalyst is the planned Q4 2026 Biologics License Application (BLA) submission to the U.S. FDA for ANKTIVA in BCG-naïve bladder cancer. Interim trial data showed statistically significant improvements in complete response duration without major safety concerns, fueling optimism. However, delays or regulatory hurdles could trigger a sharp correction. The stock’s recent surge, including a 65.3% rise in the past week, suggests investors are pricing in a successful submission, but the outcome remains binary.

Competitive pressures also weigh on sentiment. Established players like Merck’s Keytruda and Johnson & Johnson’s Inlexzo are entering the bladder cancer market, potentially limiting ANKTIVA’s pricing power and market share. While the company emphasizes ANKTIVA’s efficacy in specific subtypes, the crowded therapeutic landscape introduces uncertainty. This risk is compounded by insider selling—226,967 shares sold over 90 days—and a Pomerantz LLP investor investigation, which could amplify volatility if the BLA submission falters.

Analyst price targets underscore the market’s divided outlook. H.C. Wainwright raised its target to $15 (from $10) following Q4 results, citing $38.3 million in sequential revenue growth and global expansion. However, the consensus target of $11.73 sits within a wide range of $5.05 to $25.20, reflecting deep uncertainty. The disparity highlights the high-stakes bet on ImmunityBio’s ability to sustain growth beyond its initial launch phase. For now, the stock’s trajectory hinges on the BLA submission and its ability to navigate competitive and regulatory headwinds.

The valuation remains stretched, with the current price reflecting a future where ANKTIVA dominates its therapeutic niche. Yet, near-term risks—including high short interest, legal overhangs, and execution challenges—could trigger a “sell the news” reaction if the BLA submission is delayed or if commercialization falls short of expectations. While the company’s EU and MENA distribution partnerships signal progress, converting regulatory approvals into sustained revenue will require overcoming pricing pressures and market access hurdles. The next few months will determine whether the hype surrounding ANKTIVA can justify its current valuation or if the market will reassess its growth potential.